Medpace Holdings (MEDP) Stock Forecast & Price Target

Medpace Holdings is benefiting from a strong late-stage CRO demand backdrop, with record 3Q net new business awards of $873 million, LTM awards up 23.9% year over year, and management expecting gross and net bookings to keep improving through 2026. The company’s win rates and RFP activity are strengthening due to execution improvements rather than pricing, while cancellations remain within the normal 3-5% range and are being driven mainly by product failures, safety signals, and program reprioritization instead of funding stress. Financially, consensus points to roughly 5% revenue growth and 4.5% EBITDA growth off the current 2026 midpoint, with additional operating leverage likely as the $20 million Cincinnati expansion spend begins to lap and the facility ramps.

Medpace Holdings is exposed to a structurally volatile CRO market where government regulation, macro weakness, tighter capital markets, M&A-driven program consolidation, and a shift toward internal R&D can all reduce outsourced clinical-trial spending. Its outsized exposure to emerging biopharma has driven strong growth, but that same customer base is more prone to funding stress, cancellations, and uneven demand, which raises earnings risk despite a roughly $28 billion small- and mid-sized CRO addressable market. The concern is amplified by concentration in a few large metabolic programs, with top 5 customer revenue concentration estimated at 33% in 2Q and metabolic revenue at 30% versus 22% in 2024, creating a potential revenue headwind as those trials roll off.